Different effects of amlodipine and enalapril on the mitogen-activated protein kinase/extracellular signal-regulated kinase kinase-extracellular signal-regulated kinase pathway for induction of vascular smooth muscle cell differentiation in vivo

Hypertension Research

Volumn 29, Issue 3, 2006, Pages 179-186

  Umemoto, Seiji ^a   Kawahara, Shinji ^b   Hasmimoto, Ryo ^b   Umeji, Kyoko ^b   Matsuda, Susumu ^b   Tanaka, Masakazu ^b   Kubo, Makoto ^b   Matsuzaki, Masunori ^b  

^a YAMAGUCHI UNIVERSITY HOSPITAL   (Japan)

^b YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Calcium antagonist; Hypertension; Signal transduction; Smooth muscle cell

Indexed keywords

AMLODIPINE; ENALAPRIL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 6; MITOGEN ACTIVATED PROTEIN KINASE P38; MYOSIN HEAVY CHAIN; PROTEIN KINASE B;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; BLOOD PRESSURE MEASUREMENT; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; FIBROSIS; HYPERTENSION; IN VIVO STUDY; MALE; NONHUMAN; PHENOTYPE; RANDOMIZATION; RAT; SIGNAL TRANSDUCTION; SMOOTH MUSCLE CONTRACTILITY; SPONTANEOUSLY HYPERTENSIVE RAT; SYSTOLIC BLOOD PRESSURE; VASCULAR SMOOTH MUSCLE;

AMLODIPINE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; AORTA, THORACIC; CALCIUM CHANNEL BLOCKERS; CELL DIFFERENTIATION; ENALAPRIL; MALE; MAP KINASE SIGNALING SYSTEM; MYOCYTES, SMOOTH MUSCLE; RATS; RATS, INBRED SHR; RATS, INBRED WKY;

EID: 33646027287     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.29.179     Document Type: Article

References (38)

1. Owens GK: Regulation of differentiation of vascular smooth muscle cells. Physiol Rev 1995; 75: 487-517.
2. Fujii K, Umemoto S, Fujii A, et al: Angiotensin II type I receptor antagonist downregulates nonmuscle myosin heavy chains in spontaneously hypertensive rat aorta. Hypertension 1999; 33: 975-980.
3. Kawahara S, Umemoto S, Tanaka M, et al: Up-regulation of Akt and eNOS induces vascular smooth muscle cell differentiation in hypertension in vivo. J Cardiovasc Pharmacol 2005; 45: 367-374.
4. Kubo M, Umemoto S, Fujii K, et al: Effects of angiotensin II type 1 receptor antagonist on smooth muscle cell phenotype in intramyocardial arteries from spontaneously hypertensive rats. Hypertens Res 2004; 27: 685-693.
5. Hayashi K, Takahashi M, Kimura K, et al: Changes in the balance of phosphoinositide 3-kinase/protein kinase B (Akt) and the mitogen-activated protein kinases (ERK/p38MAPK) determine a phenotype of visceral and vascular smooth muscle cells. J Cell Biol 1999; 145: 727-740.
6. Opie LH, Schall R: Evidence-based evaluation of calcium channel blockers for hypertension: equality of mortality and cardiovascular risk relative to conventional therapy. J Am Coll Cardiol 2002; 39: 315-322.
7. Staessen JA, Wang JG, Thijs L: Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 2001; 358: 1305-1315.
8. Staessen JA, Li Y, Thijs L, et al: Blood pressure reduction and cardiovascular prevention: an update including the 2003-2004 secondary prevention trials. Hypertens Res 2005; 28: 385-407.
9. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.
10. Mason RP, Marche P, Hintze TH: Novel vascular biology of third-generation L-type calcium channel antagonists: ancillary actions of amlodipine. Arterioscler Thromb Vasc Biol 2003; 23: 2155-2163.
11. Pitt B, Byington RP, Furberg CD, et al, for the PREVENT Investigators: Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation 2000; 102: 1503-1510.
12. Nissen SE, Tuzcu EM, Libby P, et al: Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004; 292: 2217-2225.
13. Umemoto S, Tanaka M, Kawahara S, et al: Calcium antagonist reduces oxidative stress by upregulating Cu/Zn superoxide dismutase in stroke-prone spontaneously hypertensive rats. Hypertens Res 2004; 27: 877-885.
14. Ishimitsu T, Kobayashi T, Honda T, et al: Protective effects of an angiotensin II receptor blocker and a long-acting calcium channel blocker against cardiovascular organ injuries in hypertensive patients. Hypertens Res 2005; 28: 351-359.
15. Mason RP: Mechanisms of plaque stabilization for the dihydropyridine calcium channel blocker amlodipine: review of the evidence. Atherosclerosis 2002; 165: 191-199.
16. Umemoto S, Sellers JR: Characterization of in vitro motility assays using smooth muscle and cytoplasmic myosins. J Biol Chem 1990; 265: 14864-14869.
17. Sobue K, Hayashi K, Nishida W: Molecular mechanism of phenotypic modulation of smooth muscle cells. Horm Res 1998; 50 (Suppl 2): 15-24.
18. Gollasch M, Haase H, Ried C, et al: L-type calcium channel expression depends on the differentiated state of vascular smooth muscle cells. FASEB J 1998; 12: 593-601.
19. Stepien O, Zhang Y, Zhu D, et al: Dual mechanism of action of amlodipine in human vascular smooth muscle cells. J Hypertens 2002; 20: 95-102.
20. Berridge MJ: Unlocking the secrets of cell signaling. Annu Rev Physiol 2005; 67: 1-21.
21. Yamagata K, Ichinose S, Tagami M: Amlodipine and carvedilol prevent cytotoxicity in cortical neurons isolated from stroke-prone spontaneously hypertensive rats. Hypertens Res 2004; 27: 271-282.
22. Stepien O, Gogusev J, Zhu DL, et al: Amlodipine inhibition of serum-, thrombin-, or fibroblast growth factor-induced vascular smooth-muscle cell proliferation. J Cardiovasc Pharmacol 1998; 31: 786-793.
23. Ko Y, Totzke G, Graack GH, et al: Action of dihydropyridine calcium antagonists on early growth response gene expression and cell growth in vascular smooth muscle cells. J Hypertens 1993; 11: 1171-1178.
24. Mancini GB: Antiatherosclerotic effects of calcium channel blockers. Prog Cardiovasc Dis 2002; 45: 1-20.
25. Zhang YZ, Gao PJ, Wang XY, et al: The inhibitory mechanisms of amlodipine in human vascular smooth muscle cell proliferation. Hypertens Res 2000; 23: 403-406.
26. Lai YM, Fukuda N, Su JZ, et al: Novel mechanisms of the antiproliferative effects of amlodipine in vascular smooth muscle cells from spontaneously hypertensive rats. Hypertens Res 2002; 25: 109-115.
27. Jackson CL, Bush RC, Bowyer DE: Mechanism of anti-atherogenic action of calcium antagonists. Atherosclerosis 1989; 80: 17-26.
28. Laplante MA, Wu R, El Midaoui A, et al: NAD(P)H oxidase activation by angiotensin II is dependent on p42/44 ERK-MAPK pathway activation in rat's vascular smooth muscle cells. J Hypertens 2003; 21: 927-936.
29. Touyz RM, El Mabrouk M, He G, et al: Mitogen-activated protein/ extracellular signal-regulated kinase inhibition attenuates angiotensin II-mediated signaling and contraction in spontaneously hypertensive rat vascular smooth muscle cells. Circ Res 1999; 84: 505-515.
30. Su B, Mitra S, Gregg H, et al: Redox regulation of vascular smooth muscle cell differentiation. Circ Res 2001; 89: 39-46.
31. Ushio-Fukai M, Alexander RW, Akers M, et al: Reactive oxygen species mediate the activation of Akt/protein kinase B by angiotensin II in vascular smooth muscle cells. J Biol Chem 1999; 274: 22699-22704.
32. Reusch HP, Zimmermann S, Schaefer M, et al: Regulation of Raf by Akt controls growth and differentiation in vascular smooth muscle cells. J Biol Chem 2001; 276: 33630-33637.
33. On YK, Kim CH, Oh BH, et al: Effects of angiotensin converting enzyme inhibitor and calcium antagonist on endothelial function in patients with essential hypertension. Hypertens Res 2002; 25: 365-371.
34. Berkels R, Taubert D, Rosenkranz A, et al: Vascular protective effects of dihydropyridine calcium antagonists. Involvement of endothelial nitric oxide. Pharmacology 2003; 69: 171-176.
35. Gohlke P, Stoll M, Lamberty V, et al: Cardiac and vascular effects of chronic angiotensin converting enzyme inhibition at subantihypertensive doses. J Hypertens Suppl 1992; 10: S141-S144.
36. Touyz RM, Deschepper C, Park JB, et al: Inhibition of mitogen-activated protein/extracellular signal-regulated kinase improves endothelial function and attenuates Ang II-induced contractility of mesenteric resistance arteries from spontaneously hypertensive rats. J Hypertens 2002; 20:1127-1134.
37. Stegemann JP, Hong H, Nerem RM: Mechanical, biochemical, and extracellular matrix effects on vascular smooth muscle cell phenotype. J Appl Physiol 2005; 98: 2321-2327.
38. Raines EW, Ferri N: Thematic review series: the immune system and atherogenesis. Cytokines affecting endothelial and smooth muscle cells in vascular disease. J Lipid Res 2005; 46: 1081-1092.